Radiotheranostics Market Size, Application, Material, Region And Growth Forecast To 2033

The new report published by The Business Research Company, titled Radiotheranostics Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the radiotheranostics market size has grown rapidly in recent years. It will grow from $7.57 billion in 2023 to $8.74 billion in 2024 at a compound annual growth rate (CAGR) of 15.3%. The radiotheranostics market size is expected to see rapid growth in the next few years. It will grow to $14.61 billion in 2028 at a compound annual growth rate (CAGR) of 13.7%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12270&type=smp

Rising Prevalence Of Cancer To Drive Market Growth
The increasing prevalence of cancer is expected to propel the growth of the radiotheranostics market going forward. Cancer is a condition in which some cells in the body develop uncontrollably and spread to other regions of the body. Radiotheranostics medicines are commonly employed in cancer to offer the ultimate notion of customized medicine by using paired diagnostic and therapeutic radionuclide probes for the selective and targeted detection and treatment of specific (typically cancer) cells, each of which is suited to the patient's underlying condition to enhance treatment efficiency and better clinical output. For instance, according to Cancer Research UK, a UK-based cancer research organization, approximately 18 million new cancer cases were detected in 2020. Further, there would be 28 million new cancer cases globally each year by 2040, a 54.9% increase over 2020, and is predicted to be more prominent in males (60.6% increase) than girls (48.8% increase). Therefore, the increasing prevalence of cancer drives the radiotheranostics market.

Product Innovations Transforming The Radiotheranostics Market
Product innovations are a key trend gaining popularity in the radiotheranostics market. Significant companies are concentrating their efforts on creating innovative products to strengthen their position in the market. For instance, in May 2023, Advanced Cyclotron Systems Inc., a Canada-based company that supplies and services cyclotrons predominantly used for producing medical isotopes, introduced TR-ALPHA for producing alpha-emitting radioisotopes to treat cancer. It is an appropriate solution to the market demand for a low-cost cyclotron capable of producing vast amounts of Astatine-211, one of the most promising alpha-emitting radioisotopes. The TR-ALPHA is also far smaller, less costly, and simpler to run than previous cyclotron models capable of manufacturing alpha-emitting radioisotopes. It is the ideal solution for hospitals, researchers, and institutions interested in running a dedicated cyclotron to efficiently produce enormous amounts of therapeutic alpha-emitting radioisotopes.

The radiotheranostics market covered in this report is segmented -

1) By Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, Fludeoxyglucose-18F, Yttrium-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Other Radioisotopes
2) By Approach: Targeted Therapeutic, Targeted Diagnostic
3) By Application: Oncology, Non-Oncology
4) By End-Users: Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12270&type=discount

Major companies operating in the radiotheranostics market report are Lantheus Holdings Inc., Cardinal Health Inc., GE Healthcare Inc., Bayer AG, Novartis AG, Siemens Healthineers, Boston Scientific Corporation, Terumo Corporation, Orano Med, Curium SAS, IBA Molecular, The Eckert & Ziegler Group, Advanced Accelerator Applications (AAA), Telix Pharmaceuticals Limited., Abdera Therapeutics, Blue Earth Diagnostics, Sirtex Medical Limited, Y-mAbs Therapeutics Inc., ITM Radiopharma, NorthStar Medical Radioisotopes LLC, Trasis S.A., Molecular Targeting Technologies Inc., RadioMedix Inc, Clarity Pharmaceuticals, Actinium Pharmaceuticals Inc., Navidea Biopharmaceuticals Inc.

Contents of the report:
1. Executive Summary
2. Radiotheranostics Market Report Structure
3. Radiotheranostics Market Trends And Strategies
4. Radiotheranostics Market - Macro Economic Scenario
5. Radiotheranostics Market Size And Growth
…..
27. Radiotheranostics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/radiotheranostics-global-market-report

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.